$500K for Alzheimer’s Diagnostic

NeuroQuest has received $500,000 for a novel blood test for early detection of Alzheimer’s and other forms of dementia. The funding round was led by the InterTech Group in South Carolina and the Maryland/Israel Trendlines Fund and will enable a clinical trial at four US medical centers.

Its first human trials in Israel showed NeuroQuest’s test — which is based on 20 years of research by Prof. Michal Schwartz of the Weizmann Institute of Science — to be 87 percent accurate with an 85% specificity rate in detecting Alzheimer’s and ALS, two common neurodegenerative diseases. NeuroQuest hopes to provide the same early-warning capability to people in the first stages of Alzheimer’s, ALS, Parkinson’s and other progressive neurodegenerative diseases.

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.